| DB ID | MyCo_1734 |
| Title | Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis |
| Year | 2008 |
| PMID | 17898016 |
| Fungal Diseases involved | Allergic bronchopulmonary aspergillosis |
| Associated Medical Condition | Cystic fibrosis |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | The Ethics Committee of Berne (Berne, Switzerland) approved the study and written consent was obtained on enrolment. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | rAsp f3 |
| Biomarker Full Name | Specific Immunoglobulin E against recombinant A. fumigatus allergens rAsp f3 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Switzerland |
| Cohort | From 1998 onwards, a group of 48 patients (23 females and 25 males; median (interquartile range (IQR)) age 9 (7–14) yrs) with CF were systematically followed longitudinally. All patients underwent careful clinical assessment, lung function testing and microbiological diagnosis at all visits during the study period. |
| Cohort No. | 48 |
| Age Group | Jul-14 |
| P Value | None |
| Sensitivity | 0.659 |
| Specificity | 0.859 |
| Positive Predictive Value | 0.047 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary hypersensitivity disease mediated by an allergic response to Aspergillus fumigatus. ABPA occurs in,10% of cystic fibrosis (CF) patients and may lead to acute worsening of respiratory status and ongoing decline in lung function, ultimately progressing to a chronic state and lung fibrosis without adequate treatment. Despite the existence of the gold-standard Nelson criteria, diagnosis of ABPA in CF patients remains difficult. The wide variation in diagnostic practices between clinics, different estimates of prevalence and a delay in recognition lead to undertreatment. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | ELISA kit (R&D Systems, Minneapolis, MN, USA) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
